相关实验视频

Updated: Jul 26, 2025

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

激活PIK3CA突变和早期侵袭性叶状乳腺癌治疗辅助全身治疗的结果之间的关联

Domen Ribnikar^1,2, Valentina Jeric Horvat¹, Ivica Ratosa^2,3

¹Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia.

Radiology and oncology

|June 21, 2023

概括

激活PIK3CA突变不会影响侵袭性叶状癌 (ILC) 的存活率. 然而,PIK3CA突变与患者接受他莫西芬或芳酶抑制剂时死亡风险降低有关.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
临床研究临床研究

背景情况:

侵袭性叶状癌 (ILC) 是乳腺癌的一个亚型.
激活PIK3CA的突变在各种癌症中很常见.
在ILC中PIK3CA突变的预后作用及其与内分泌疗法 (ET) 疗效的关联尚未明确.

研究的目的:

评估可操作ILC中的PIK3CA激活突变的预后意义.
研究PIK3CA激活突变与ILC患者辅助内分泌治疗 (ET) 的有效性之间的关联.

主要方法:

一项单一机构的研究分析了2003-2008年期间治疗的早期ILC患者.
使用定量PCR检测到PIK3CA激活突变.
使用Kaplan-Meier和Cox比例危险模型分析了生存结果 (远程无转移生存[DMFS]和整体生存[OS]).

主要成果:

在365名ILC患者中,有45%具有PIK3CA激活突变.
PIK3CA突变没有显著影响DMFS或OS (p = 0.36和p = 0.42).
在PIK3CA突变患者中,每年服用塔莫西芬 (TAM) 或芳香酶抑制剂 (AI) 的患者,死亡风险分别降低了27%和21%.

结论:

在早期的ILC中,PIK3CA激活突变似乎不会影响DMFS或OS.
患有PIK3CA突变的患者在接受TAM或AI治疗时,死亡风险显著降低.

关键词:

这是一种PIK3CA突变.内分泌疗法是一种内分泌疗法.侵袭性叶膜癌的基因组学侵袭性叶片性癌瘤 (lobular carcinoma) 是一种侵入性叶片性癌症.

更多相关视频

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

相关概念视频

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...